Squarepoint Ops LLC Buys 17,301 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE)

Squarepoint Ops LLC boosted its holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) by 90.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 36,344 shares of the company's stock after acquiring an additional 17,301 shares during the quarter. Squarepoint Ops LLC owned about 0.08% of Apogee Therapeutics worth $1,646,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the business. Driehaus Capital Management LLC raised its holdings in Apogee Therapeutics by 2.8% during the 4th quarter. Driehaus Capital Management LLC now owns 2,605,310 shares of the company's stock worth $118,021,000 after buying an additional 71,703 shares during the period. Alliancebernstein L.P. increased its holdings in shares of Apogee Therapeutics by 13.5% in the 4th quarter. Alliancebernstein L.P. now owns 1,355,185 shares of the company's stock valued at $61,390,000 after purchasing an additional 160,822 shares during the period. Paradigm Biocapital Advisors LP increased its holdings in shares of Apogee Therapeutics by 82.9% in the 4th quarter. Paradigm Biocapital Advisors LP now owns 1,283,766 shares of the company's stock valued at $58,155,000 after purchasing an additional 581,949 shares during the period. Janus Henderson Group PLC increased its holdings in shares of Apogee Therapeutics by 141.7% in the 4th quarter. Janus Henderson Group PLC now owns 1,135,100 shares of the company's stock valued at $51,455,000 after purchasing an additional 665,543 shares during the period. Finally, Price T Rowe Associates Inc. MD increased its holdings in shares of Apogee Therapeutics by 38.8% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,052,595 shares of the company's stock valued at $47,683,000 after purchasing an additional 294,514 shares during the period. 79.04% of the stock is currently owned by institutional investors.

Apogee Therapeutics Trading Up 2.1%

APGE stock traded up $0.75 during midday trading on Tuesday, hitting $37.08. The stock had a trading volume of 685,613 shares, compared to its average volume of 530,510. The firm has a market capitalization of $1.71 billion, a price-to-earnings ratio of -15.32 and a beta of 1.70. Apogee Therapeutics, Inc. has a 52 week low of $26.20 and a 52 week high of $63.50. The stock has a 50-day simple moving average of $36.34 and a 200 day simple moving average of $39.66.

Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The company reported ($0.95) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.19) by $0.24. On average, equities analysts forecast that Apogee Therapeutics, Inc. will post -3.09 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. Wedbush reiterated an "outperform" rating and issued a $90.00 target price on shares of Apogee Therapeutics in a report on Tuesday, March 11th. Guggenheim reaffirmed a "buy" rating on shares of Apogee Therapeutics in a research report on Monday, February 10th. Finally, Citigroup began coverage on Apogee Therapeutics in a report on Thursday, March 13th. They set a "buy" rating and a $95.00 price target for the company. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $94.60.

Insiders Place Their Bets

In related news, CEO Michael Thomas Henderson sold 10,000 shares of Apogee Therapeutics stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $30.15, for a total value of $301,500.00. Following the completion of the sale, the chief executive officer now directly owns 1,292,987 shares in the company, valued at $38,983,558.05. This trade represents a 0.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Carl Dambkowski sold 3,860 shares of Apogee Therapeutics stock in a transaction dated Wednesday, April 2nd. The stock was sold at an average price of $36.22, for a total value of $139,809.20. Following the completion of the sale, the insider now owns 247,173 shares of the company's stock, valued at approximately $8,952,606.06. The trade was a 1.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 18,175 shares of company stock worth $587,191 over the last three months. 42.77% of the stock is currently owned by corporate insiders.

Apogee Therapeutics Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.